Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
M&A is back, but how often do deals pay off?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.